China NMPA accepts Astellas’ sBLA for urothelial cancer treatment
2024-03-29
临床结果临床3期上市批准抗体药物偶联物
Preview
来源: Pharmaceutical Technology
Astellas Pharma’s enfortumab vedotin is a Nectin-4- targeted antibody-drug conjugate. Credit: BalkansCat / Shutterstock.com.
The Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted Astellas Pharma’s supplemental biologics license application (sBLA) for enfortumab vedotin plus KEYTRUDA (pembrolizumab) for urothelial cancer.
This combination therapy is aimed at treating adult patients with previously untreated locally advanced or metastatic urothelial cancer (la/mUC).
Enfortumab vedotin is a targeted antibody-drug conjugate (ADC) directed against the Nectin-4 protein.
The potential approval for the combination regimen could revolutionise the standard of care for first-line la/mUC, offering an alternative to the platinum-containing chemotherapy that is currently administered.
The sBLA is based on the data from the randomised, open-label, controlled Phase III EV-302 clinical trial, also known as KEYNOTE-A39.
See Also:
Arvinas gets grant for treatment of prostate cancer with specific compounds
Preview
来源: Pharmaceutical Technology
Chong Kun Dang Pharmaceutical gets grant for injectable composition of testosterone undecanoate for testosterone deficiency treatment
Preview
来源: Pharmaceutical Technology
This study compared enfortumab vedotin in combination with pembrolizumab to platinum-containing chemotherapy in 886 patients.
Overall survival (OS) and progression-free survival (PFS) were the trial’s primary outcomes.
Secondary endpoints included objective response rate (ORR), duration of response (DOR), and safety profiles.
The results demonstrated that the combination of enfortumab vedotin with pembrolizumab significantly improved OS and PFS, with meaningful clinical outcomes when compared to the standard chemotherapy regimen.
The safety profile of the combination therapy was in line with prior reports without any new safety concerns identified.
In addition to the CDE’s review, the NMPA is considering enfortumab vedotin as a treatment option for la/mUC patients who have previously undergone therapy with a PD-1/L1 inhibitorPD-1/L1 inhibitor and platinum-based chemotherapy.
Parallelly, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) and Japan’s Ministry of Health, Labour and Welfare (MHLW) are also reviewing the combination regimen.
In December last year, the US Food and Drug Administration granted approval for this combination therapy.
Astellas Oncology Development head and senior vice-president Ahsan Arozullah said: “Locally advanced or metastatic urothelial cancer is a life-threatening condition in China with nearly half of those diagnosed succumbing to the disease.
“The CDE’s acceptance of our sBLA for enfortumab vedotin and pembrolizumab brings us one step closer to delivering a much-needed, innovative new treatment option for this patient population.”
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。